Lurie Cancer Center | November 12 …Do I Need Therapy for My Stage II or Stage III Melanoma? Jeffrey Wayne, MD, FACS 5:55 PM What are…
Taking Care of You, The Caregiver …one with melanoma meet his/her needs. And yet, what about you? We will now discuss your needs as the caregiver and strategies…
UPMC Hillman Cancer Center | March 16, 2024 This virtual and in-person symposium is presented by AIM at Melanoma and UPMC Hillman Cancer Center held at UPMC Hillman…
Our Industry Partners v2 About AIM\n\n Our Mission\n\n Our Industry Partners\n\n Our Corporate and Non-Profit Partners\n\n Our Global Influence\n\n Blog – Melanoma360\n\n Newsletters &…
Take Action Against Indoor Tanning Take Action Against Indoor Tanning Indoor tanning before 18 years of age increases one’s risk of melanoma by 85% and…
Planned Giving Your legacy can fund melanoma research. Leaving a gift to AIM as part of your estate is a wonderful…
Steps Against Melanoma: An Interview with Cindy LeBlanc, AIM at Melanoma’s National Director of Walks & Events No excerpt…
Fundraising 101 FUNDRAISING 101 Anyone can fundraise! Whether you host a bake sale, coordinate an AIM Steps Against Melanoma Walk, pledge your birthday,…
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026 Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026 Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026 Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)